Suppression of Mouse AApoAII Amyloidosis Progression by Daily Supplementation with Oxidative Stress Inhibitors.

Abstract

Amyloidosis is a group of diseases characterized by protein misfolding and aggregation to form amyloid fibrils and subsequent deposition within various tissues. Previous studies have indicated that amyloidosis is often associated with oxidative stress. However, it is not clear whether oxidative stress is involved in the progression of amyloidosis. We administered the oxidative stress inhibitors tempol and apocynin via drinking water to the R1.P1-Apoa2c mouse strain induced to develop mouse apolipoprotein A-II (AApoAII) amyloidosis and found that treatment with oxidative stress inhibitors led to reduction in AApoAII amyloidosis progression compared to an untreated group after 12 weeks, especially in the skin, stomach, and liver. There was no effect on ApoA-II plasma levels or expression of Apoa2 mRNA. Detection of the lipid peroxidation markers 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) revealed that the antioxidative effects of the treatments were most obvious in the skin, stomach, and liver, which contained higher levels of basal oxidative stress. Moreover, the unfolded protein response was reduced in the liver and was associated with a decrease in oxidative stress and amyloid deposition. These results suggest that antioxidants can suppress the progression of AApoAII amyloid deposition in the improved microenvironment of tissues and that the effect may be related to the levels of oxidative stress in local tissues. This finding provides insights for antioxidative stress treatment strategies for amyloidosis.

• Authors: Jian Dai, Xin Ding, Hiroki Miyahara, Zhe Xu, Xiaoran Cui, Yuichi Igarashi, Jinko Sawashita, Masayuki Mori, Keiichi Higuchi
• Journal: Oxidative medicine and cellular longevity (Oxid Med Cell Longev) Vol. 2019 Pg. 1263274 ( 2019) ISSN: 1942-0994 [Electronic] United States
• PMID: 31281565 (Publication Type: Journal Article)

Chemical References

• Apolipoprotein A-II
• amyloidogenic apolipoprotein A-II, mouse

Topics

• Amyloidosis (drug therapy, pathology)
• Animals
• Apolipoprotein A-II (antagonists & inhibitors)
• Dietary Supplements (standards)
• Disease Progression
• Female
• Mice
• Oxidative Stress (drug effects)